People: AMAG Pharmaceuticals Inc (AMAG.OQ)
AMAG.OQ on NASDAQ Stock Exchange Global Select Market
23.61USD
1 Aug 2013
23.61USD
1 Aug 2013
Price Change (% chg)
$1.11 (+4.93%)
$1.11 (+4.93%)
Prev Close
$22.50
$22.50
Open
$23.15
$23.15
Day's High
$23.72
$23.72
Day's Low
$22.92
$22.92
Volume
22,309
22,309
Avg. Vol
36,596
36,596
52-wk High
$25.63
$25.63
52-wk Low
$13.90
$13.90
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
William Heiden |
53 | 2012 | President, Chief Executive Officer, Director |
Scott Holmes |
38 | 2012 | Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Controller, Treasurer |
Frank Thomas |
43 | 2012 | Chief Operating Officer, Executive Vice President |
Greg Madison |
45 | 2013 | Executive Vice President, Chief Commercial Officer |
Scott Townsend |
46 | 2012 | Senior Vice President - Legal Affairs, General Counsel, Secretary |
Steven Caffe |
2013 | Senior Vice President, Chief Development and Regulatory Officer | |
Carol Satler |
2013 | Senior Vice President - Medical and Scientific Affairs | |
Christopher White |
51 | 2011 | Chief Business Officer, Senior Vice President |
Scott McMillan |
54 | 2012 | Executive Director - Manufacturing Operations |
Michael Narachi |
53 | 2006 | Independent Director |
Robert Perez |
48 | 2009 | Independent Director |
Lesley Russell Cooper |
52 | 2009 | Independent Director |
Gino Santini |
56 | 2012 | Independent Director |
Davey Scoon |
66 | 2006 | Independent Director |
Amy Sullivan |
Vice President - Corporate Communication, Investor Relation |
Biographies
| Name | Description |
|---|---|
William Heiden |
Mr. William K. Heiden is President, Chief Executive Officer, Director of AMAG Pharmaceuticals, Inc. Prior to joining the Company, he was the President and Chief Executive Officer of GTC Biotherapeutics, Inc., now rEVO Biologics, Inc., a pharmaceutical company, from June 2010 to May 2012 and continues to serve as its non-executive Chairman. Mr. Heiden was President and Chief Executive Officer and a member of the Board of Directors of Elixir Pharmaceuticals, Inc., or Elixir, a pharmaceutical company, from September 2004 until December 2008. Prior to joining Elixir, he served as President and Chief Operating Officer of Praecis Pharmaceuticals, Inc., a public biopharmaceutical company which was subsequently acquired by GlaxoSmithKline plc, from May 2002 to September 2004. From 1987 to 2002, Mr. Heiden held various positions of increasing responsibility at Schering-Plough Corporation, now Merck & Co., including managing a number of businesses in the United States, Europe and Canada. He serves on the Board of Directors of LFB Biotechnologies S.A.S., a private French biotechnology company. Mr. Heiden holds a B.A. from the University of Florida, an M.B.A. from Cornell University's Johnson Graduate School of Management, and a M.I.M. from the University of Louvain. |
Scott Holmes |
Mr. Scott A. Holmes is Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Controller, Treasurer of AMAG Pharmaceuticals, Inc. He joined in September 2011 as Vice President of Finance and Controller. He became Chief Accounting Officer in December 2011 and Principal Financial Officer and Treasurer in March 2012. Prior to joining Mr. Holmes served as Vice President of Finance and Treasurer of Molecular Biometrics, Inc., a commercial stage medical diagnostics company, from June 2010 to September 2011. From August 2009 to May 2010, Mr. Holmes was Vice President of Finance and Administration at On-Q-ity Inc., an oncology diagnostics company. He served as a consultant with Altman & Company, a consulting firm, from January 2009 to August 2009. Prior to 2009, Mr. Holmes spent five years at Dynogen Pharmaceuticals, Inc., a privately held pharmaceutical company, as Vice President of Finance and Administration and Treasurer. He also served as the Controller at Keryx Biopharmaceuticals, Inc., a public biotechnology company from November 2001 to October 2003. Mr. Holmes holds a B.A. in History from Middlebury College and a dual M.S./M.B.A. degree from Northeastern University Graduate School of Business Administration. |
Frank Thomas |
Mr. Frank E. Thomas is Chief Operating Officer, Executive Vice President of AMAG Pharmaceuticals Inc. He joined in August 2011 as Executive Vice President, Chief Financial Officer and Treasurer and currently serves as Executive Vice President and Chief Operating Officer. From November 2011 to May 2012, he also served as Interim President and Chief Executive Officer. Prior to joining, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., or Molecular Biometrics, a commercial stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., or Critical Therapeutics, a public biopharmaceutical company, from 2004 to 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the Board of Directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas was the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc. Since 2007, he has been a member of the Board of Directors of the Massachusetts Biotechnology Council. Mr. Thomas holds a B.B.A. in Business Administration from the University of Michigan, Ann Arbor. |
Greg Madison |
Mr. Greg Madison is Executive Vice President, Chief Commercial Officer of AMAG Pharmaceuticals, Inc. Mr. Madison spent 12 years at Genzyme Corporation, a Sanofi company, or Genzyme, a public biotechnology company, in various commercial roles of increasing responsibility, most recently as Vice President and General Manager of its Global Renal Division. Prior to joining Genzyme, Mr. Madison spent five years at Janssen Pharmaceuticals, Inc., a wholly-owned subsidiary of Johnson & Johnson, from 1995 to 2000, in sales and sales management roles, and began his career in the pharmaceutical industry in sales with Wyeth-Ayerst International, Inc., a private pharmaceutical products manufacturer from 1994 to 1995. From 2011 to 2013, he was a member of the Board of Directors, and a member of the Operations Committee, of Kidney Care Partners, a Washington D.C.-based organization focused on legislative, regulatory and public policy issues related to patients with chronic kidney disease. Mr. Madison holds a B.B.A. in Finance from the University of Massachusetts, Amherst. |
Scott Townsend |
Mr. Scott B. Townsend is Senior Vice President - Legal Affairs, General Counsel, Secretary of AMAG Pharmaceuticals Inc. In December 2009, Mr. Townsend founded External GC Law Group and until August 2012, provided legal advice to a variety of life science companies, including biopharmaceutical and medical device companies. From October 2008 to June 2009, he served as Executive Vice President of Legal Affairs, General Counsel and Secretary for Cornerstone Therapeutics Inc., a public specialty pharmaceutical company. From August 2004 to October 2008, Mr. Townsend served as Senior Vice President, General Counsel and Secretary for Critical Therapeutics, a public biopharmaceutical company. From August 2000 to August 2004, he was a junior partner in the corporate department at Hale and Dorr LLP, now Wilmer Cutler Pickering Hale and Dorr LLP. Prior to joining Hale and Dorr LLP, Mr. Townsend served as a corporate lawyer at Goodwin Procter LLP in Boston, MA and Kilpatrick Stockton LLP in North Carolina. Mr. Townsend received his A.B. from Bowdoin College with a double-major in Economics and Government and Legal Studies and his J.D. from The University of Virginia School of Law. |
Steven Caffe |
Dr. Steven Caffe, M.D., is Senior Vice President, Chief Development and Regulatory Officer of AMAG Pharmaceuticals, Inc. He brings 20 years of experience in global biopharmaceuticals development and regulatory approvals to AMAG. He joins AMAG from MedImmune, AstraZeneca's global biologics research and development arm, where he most recently served as senior vice president of global regulatory affairs and patient safety. Dr. Caffé has broad-based industry experience across several therapeutic areas, and in the development of biopharmaceuticals and medical devices. Early in his career, Dr. Caffé served as a medical director for Parke-Davis, before its acquisition by Pfizer, and has since had roles of increasing responsibility at pharmaceutical companies. Through his experience at Merck & Co., Sanofi, Baxter and most recently MedImmune, Dr. Caffé has assembled and led high-performing teams through many development and regulatory programs, achieving key new product approvals and extending the life cycle of several commercial products. Dr. Caffé received his medical degree from the Faculté de Médecine Saint-Antoine, Université Pierre et Marie Curie (Paris 6), completed his internship and residency, and practiced medicine at the academic hospitals of the Assistance Publique de Paris with a focus on emergency and intensive care. |
Carol Satler |
Dr. Carol Satler, M.D., Ph.D., is Senior Vice President - Medical and Scientific Affairs of AMAG Pharmaceuticals, Inc. Dr. Satler brings to AMAG more than 25 years of healthcare experience, including 15 years in the global biopharmaceutical industry and 10 years in clinical practice. Prior to joining AMAG, Dr. Satler served in executive clinical development and medical affairs roles at Pfizer and Sanofi, as well as Forest Labs and Millenium. Dr. Satler has broad-based industry experience and has led and managed teams across several therapeutics areas. She has held leadership roles in medical affairs, clinical research and development and administration both in the U.S. and globally. Dr. Satler has formulated strategic clinical development plans, life cycle management and commercialization of products. Dr. Satler received her medical degree and Ph.D. from Case Western Reserve University, completed her internship and residency, and practiced medicine at the Boston Children's Hospital with a focus on cardiology. |
Christopher White |
Mr. Christopher G. White is Chief Business Officer, Senior Vice President of AMAG Pharmaceuticals Inc. He joined in September 2007 as Vice President of Business Development and Corporate Planning. Mr. White was promoted to Senior Vice President of Business Development and Corporate Planning in May 2008 and to Senior Vice President and Chief Business Officer in November 2011. From 2005 through 2007, Mr. White was a Partner in the Pharmaceutical and Medical Products Practice at Accenture. Prior to Accenture, he was a Vice President and Partner in the Pharmaceuticals and Healthcare Practice at A.T. Kearney, Inc. from 1998 to 2005. From 1984 to 1998, Mr. White held positions of increasing responsibility at DuPont Pharmaceuticals Company, Merck & Co. Inc. and Arthur D. Little, respectively. Mr. White holds a B.S. in Chemical Engineering from Tufts University and an M.B.A. from Columbia University. |
Scott McMillan |
Dr. Scott T. McMillan is Executive Director - Manufacturing Operations of AMAG Pharmaceuticals Inc. Dr. McMillan was promoted to Head of Quality and Vice President, Technical Operations in March 2010 and to Senior Vice President, Quality and Technical Operations in January 2013. Prior to joining , Dr. McMillan spent three years at AVANT Immunotherapeutics, Inc., now Celldex Therapeutics, Inc., a public biopharmaceutical company, in various manufacturing operations and process development positions of increasing responsibility, most recently as Senior Director, Manufacturing Operations/Process Development. Prior to 2005, he was Director, Purification Operations, at Johnson Matthey Pharmaceutical Materials, Inc., an international specialty chemicals company. Since 2011, Dr. McMillan has been a business mentor in the Department of Chemical Engineering, or the Department, at Northeastern University and has served on the Department's Industrial Advisory Board since 2010. He has authored or co-authored more than 75 presentations and publications. Dr. McMillan holds a B.S. in Chemical Engineering from the University of Delaware and a Ph.D. in Chemical Engineering from the Georgia Institute of Technology. |
Michael Narachi |
Mr. Michael A. Narachi is Independent Director of AMAG Pharmaceuticals Inc. Mr. Narachi is currently President and Chief Executive Officer of Orexigen Therapeutics, Inc., or Orexigen, a public biopharmaceutical company. Prior to joining Orexigen in March 2009, he served as Chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a biotechnology company, from November 2006 until March 2009. He served as Executive Chairman of the Board of Directors of Naryx Pharma, Inc., a pharmaceutical company, from August 2004 to April 2008. In 2004, Mr. Narachi retired as an officer and Vice President of Amgen Inc., or Amgen, public therapeutics company, where he served as General Manager of Amgen's Anemia Business from 1999 to 2004. Mr. Narachi joined Amgen in 1984 and held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN®; Director of Clinical Operations in Thousand Oaks, CA and Cambridge, U.K.; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. Mr. Narachi received a B.S. and M.A. degree in Molecular Genetics from the University of California at Davis. He completed the Executive M.B.A. program at the Anderson Graduate School of Management at the University of California, Los Angeles. |
Robert Perez |
Mr. Robert J. Perez is Independent Director of AMAG Pharmaceuticals Inc. He is currently President and Chief Operating Officer of Cubist Pharmaceuticals, Inc., or Cubist, a public pharmaceutical company. Mr. Perez joined Cubist in March 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin® (daptomycin for injection) and served as Executive Vice President and Chief Operating Officer from August 2007 to July 2012. Prior to joining Cubist, he served as Vice President of Biogen, Inc.'s CNS business unit from 2001 to 2003, where he was responsible for commercial leadership of an $800 million neurology business unit, and from 1995 to 2001 he held positions of increasing responsibility within the commercial organization. From 1987 to 1995 Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. He also served as a member of the Board of Directors of Epix Pharmaceuticals, Inc., a public biopharmaceutical company, from 2006 to 2009. Mr. Perez has been a member of the Board of Trustees of the Dana-Farber Cancer Institute, Inc. since January 2013 and the Board of Advisors of the Citizen School of Massachusetts since 2010. Mr. Perez received a B.S. from California State University, Los Angeles and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles. |
Lesley Russell Cooper |
Dr. Lesley Russell Cooper, MB.Ch.B., MRCP, is an Independent Director of AMAG Pharmaceuticals Inc. She was Senior Vice President and Head of Research and Development for Global Branded Products at Teva Pharmaceuticals, Inc., or Teva, a public pharmaceutical company from October 2011 to June 2012. Dr. Russell was appointed to this role upon Teva's acquisition of Cephalon Inc., or Cephalon, a public pharmaceutical company, where she served as Executive Vice President and Chief Medical Officer from September 2006 to October 2011. She joined Cephalon in 2000 as Vice President, Worldwide Clinical Research. Prior to Cephalon, Dr. Russell served as Vice President, Clinical Research at US Bioscience Inc., a pharmaceutical company, and held positions of increasing responsibility within US Bioscience Inc. from 1996 to 1999. From 1995 to 1996, she was a clinical research physician at Eli Lilly U.K. and a Medical Director at Amgen U.K. from 1992 to 1995. Dr. Russell was trained in Hematology/Oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children, Edinburgh. She received an MB.Ch.B. from the University of Edinburgh, Scotland and is a member of the Royal College of Physicians, United Kingdom. Dr. Russell is registered with the General Medical Council, United Kingdom. She currently serves on the Board of Directors of Endoycte, Inc., a biopharmaceutical company, where she has been a director since January 2013. |
Gino Santini |
Mr. Gino Santini is Independent Director of AMAG Pharmaceuticals, Inc. From 1983 to 2010, Mr. Santini held a variety of commercial and operational roles at Eli Lilly and Company, or Eli Lilly, a public pharmaceutical company, serving most recently from April 2007 to December 2010 as Senior Vice President, Corporate Strategy and Business Development and as a member of the company's Executive Committee where he led corporate strategy and long-range planning, mergers and acquisitions, new product licensing and the expansion of Lilly Ventures in the United States and China. During his tenure at Eli Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, Senior Vice President of Corporate Strategy and Policy from 2004 to 2007, President of U.S. operations from 1999 to 2004 and President of the women's health franchise from 1997 to 1999. Mr. Santini currently serves on the Board of Directors of Allena Pharmaceuticals, Inc., a pharmaceuticals company, where he has been a director since February 2012. He serves on the Board of Directors of Sorin S.p.A., a global medical device company, where he has been a director since April 2012, and on the Board of Directors of Finanziaria Saccarifera Italo Iberica S.p.A., a financial holding company, where he has been a director since January 2013. Mr. Santini also serves on the Board of Directors of Collegium Pharmaceuticals, Inc., a pharmaceutical company, where he has been a director since July 2012. Mr. Santini is a past Chairman of the Board of the National Pharmaceutical Council and of Noble of Indiana, a non-profit agency serving individuals with developmental disabilities. He also served on the Board of Directors for United Way and the Executive Committee and Board of Directors of the Indianapolis Chamber of Commerce. He holds an undergraduate degree in mechanical engineering from the University of Bologna and an M.B.A. from the Simon School of Business, University of Rochester. |
Davey Scoon |
Mr. Davey S. Scoon, CPA, is Independent Director of AMAG Pharmaceuticals Inc. Mr. Scoon serves as Chairman of the Board of Directors of Tufts Health Plan, where he has been a director since 1981. He has been a member of the Board of Directors of Orthofix International, N.V., a medical device company, since June 2011 and a member of the Board of Directors of Biodel Inc., a public specialty biopharmaceutical company, since April 2012. Mr. Scoon also serves as Chairman of the Board of Trustees of Allianz Funds, a registered investment company consisting of 22 mutual funds, where he has been a director since January 2006. He was the Chairman of the Audit Committee of Cardiokine, Inc., a pharmaceutical company, where he was a director from 2005 to 2011. Mr. Scoon has been an Adjunct Assistant Professor at Tufts University School of Medicine since 2005 and a lecturer in accounting at the University of Wisconsin since 2011. He also previously served as the Chairman of the Audit Committee of NitroMed, Inc., a public pharmaceutical company, from 2003 to 2009, and a member of the Board of Directors of Inotek Pharmaceuticals Corporation, a pharmaceutical company, from 2006 to 2009. From 2003 to 2005, Mr. Scoon was Chief Administrative and Financial Officer of Tom's of Maine, a company that manufactures natural care products. From 2001 to 2003, Mr. Scoon served as Chief Financial and Administrative Officer for Sun Life Financial U.S., and from 1999 to 2001, Mr. Scoon served as Vice President and Chief Financial Officer for Sun Life Financial U.S. From 1985 to 1999, Mr. Scoon was employed by Liberty Funds Group of Boston (formerly Colonial Management) in various capacities, including Chief Financial Officer and Chief Operating Officer. Mr. Scoon holds a B.B.A. from the University of Wisconsin and an M.B.A. from Harvard Business School. |
Amy Sullivan |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
William Heiden |
3,856,820 |
Scott Holmes |
574,897 |
Frank Thomas |
1,640,730 |
Greg Madison |
-- |
Scott Townsend |
860,284 |
Steven Caffe |
-- |
Carol Satler |
-- |
Christopher White |
1,121,350 |
Scott McMillan |
-- |
Michael Narachi |
-- |
Robert Perez |
-- |
Lesley Russell Cooper |
-- |
Gino Santini |
-- |
Davey Scoon |
-- |
Amy Sullivan |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
William Heiden |
0 | 0 |
Scott Holmes |
0 | 0 |
Frank Thomas |
0 | 0 |
Greg Madison |
0 | 0 |
Scott Townsend |
0 | 0 |
Steven Caffe |
0 | 0 |
Carol Satler |
0 | 0 |
Christopher White |
0 | 0 |
Scott McMillan |
0 | 0 |
Michael Narachi |
0 | 0 |
Robert Perez |
0 | 0 |
Lesley Russell Cooper |
0 | 0 |
Gino Santini |
0 | 0 |
Davey Scoon |
0 | 0 |
Amy Sullivan |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
CAFFE STEVEN |
35,000 | $0.00 |
HEIDEN WILLIAM K |
10,000 | $12.99 |
RUSSELL COOPER LESLEY R |
2,300 | $0.00 |
SCOON DAVEY STEWART |
2,300 | $0.00 |
SANTINI GINO |
2,300 | $0.00 |
PEREZ ROBERT J |
2,300 | $0.00 |
NARACHI MICHAEL A |
3,800 | $0.00 |
ADAGE CAPITAL PARTNERS GP L L C |
50,000 | $24.00 |
HEIDEN WILLIAM K |
8,162 | $25.03 |
HEIDEN WILLIAM K |
25,000 | $0.00 |
MADISON GREG |
12,500 | $0.00 |
TOWNSEND SCOTT B |
4,400 | $0.00 |
TOWNSEND SCOTT B |
7,500 | $0.00 |
THOMAS FRANK E |
12,500 | $0.00 |
HOLMES SCOTT A |
2,500 | $0.00 |
WHITE CHRISTOPHER G |
5,000 | $0.00 |
HEIDEN WILLIAM K |
27,500 | $0.00 |
WHITE CHRISTOPHER G |
10,000 | $0.00 |
THOMAS FRANK E |
6,300 | $0.00 |
MADISON GREG |
6,300 | $0.00 |
HOLMES SCOTT A |
5,000 | $0.00 |
HEIDEN WILLIAM K |
14,400 | $0.00 |
WHITE CHRISTOPHER G |
400 | $16.37 |
WHITE CHRISTOPHER G |
433 | $16.39 |
WHITE CHRISTOPHER G |
833 | $0.00 |

